Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06581432 · ClinicalTrials.gov registry record · Phase 2
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
A Phase 2 study of Solid Tumours, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 430
- Enrollment target
- 20
- Study locations
NCT06581432: Recruiting Phase 2 study of Solid Tumours, sponsored by Boehringer Ingelheim.
NCT06581432 is a Phase 2 study of Solid Tumours that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 430 participants, above the 99-participant average among 9 other Solid Tumours trials with a reported enrollment target (334% higher). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06581432, a Phase 2 study of Solid Tumours, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 430 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers with HER2 alterations. HER2 alterations can cause cancer. Zongertinib inhibits HER2. Participants are put into 13 groups based on the type of advanced cancer and the type of HER2 alterations they have. All participants take one dose of zongertinib each day. Participants can continue the treatment as long as they benefit from it and can tolerate it. Participants visit the study site regularly. During many of the visits, the doctors check the size of the tumour and whether it has spread to other parts of the body. During all the visits, the doctors check participants' health and take note of any unwanted effects.
Primary Outcome
according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 by central independent review, and it will be summarised descriptively as absolute and relative frequencies
Conditions Studied
Interventions
- DRUG Zongertinib
Study Locations (20)
California
- Precision NextGen Oncology - Beverly Hills
- Scripps Cancer Center Torrey Pines - La Jolla
- Valkyrie Clinical Trials - Los Angeles
New York
- Icahn School of Medicine at Mount Sinai - New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- Sarah Cannon Research Institute at Mary Crowley - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
New South Wales
- Macquarie University - Macquarie Park
- GenesisCare North Shore - St Leonards
Alaska
- Alaska Oncology and Hematology, LLC - Anchorage
Arizona
- University of Arizona Comprehensive Cancer Center - Tucson
Connecticut
- Yale University School of Medicine - New Haven
Florida
- BRCR Global - Tamarac
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2024-10-11 |
| Est. Completion | 2028-12-29 |
| Phase | Phase 2 |
What NCT06581432 shows while recruiting
NCT06581432 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 99-participant average among 9 other Solid Tumours trials with a reported enrollment target (334% higher).
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 1 intervention - of which Zongertinib is the first listed.
NCT06581432 names 20 study sites across 15 states, led by California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06581432 about?
NCT06581432 is a clinical study titled "Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations". This is a study for people with advanced cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with HER2 alterations can join the study. The purpose of this study is to find out whether a medicine called zongertinib helps people with advanced cancers wit...
What is the current status of trial NCT06581432?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 430 participants. The study started on 2024-10-11. Estimated completion is 2028-12-29.
What conditions does trial NCT06581432 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT06581432?
The interventions under investigation include: Zongertinib (DRUG).
Who is sponsoring clinical trial NCT06581432?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06581432 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06581432's enrollment target sits among peer trials
430 1st of 9 higher than 9 of 9 other Solid Tumours trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumours trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine
ACTIVE NOT RECRUITING · Phase 2
-
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
COMPLETED · Phase 2
-
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI